Skip to content
OpenCapital
Get started

Summit Therapeutics SMMT Q4 2025 Annual earnings

Reported February 23, 2026 · After market close

Diluted EPS-$0.29Miss by $0.19
Revenue estimate$56.8M
EPS estimate-$0.10

Next report

Aug 10, 2026 (In 4 weeks)
Revenue estimate$108.8K
EPS estimate-$0.26

Financials

Q4 2025

Income statement

See full
Net income-$219.2M-258%
EPS (diluted)-$0.28-211%

Balance sheet

See full
Cash & equivalents$16.4M+0.6%
Total debt$20.9M+189%
Total equity$658.9M+69.5%
Total assets$751.2M+72.5%

Cash flow

See full
Operating cash flow-$101.9M-109%
CapEx$164.0K+1,071%
Free cash flow-$102.1M-110%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$13.02B-1.1%
Enterprise value$13.02B-1.0%

Returns & leverage

See full
Return on equity-206.1%-1,405pp
Debt / equity0×0.0×
Current ratio9.9×-0.3×

Versus estimates

Diluted EPS

Q1 2026-$0.24Beat by $0.09
Q4 2025-$0.29Miss by $0.19
Q3 2025-$0.31Miss by $0.13Q2 2025-$0.76Miss by $0.67Q1 2025-$0.09Beat by $0.00Q4 2024-$0.08Beat by $0.00

Ask the moment Summit Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Summit Therapeutics report Q4 2025 earnings?
Summit Therapeutics (SMMT) reported Q4 2025 earnings on February 23, 2026 after market close.
What were Summit Therapeutics's Q4 2025 revenue and EPS?
Summit Therapeutics reported diluted EPS of $-0.29 for Q4 2025.
Did Summit Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.10 by $0.19.
How did Summit Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 262.5% from $-0.08.
Where can I find Summit Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001599298-26-000014) and the 10-K periodic report (0001599298-26-000015) directly on SEC EDGAR. The filing index links above go to sec.gov.